Bruix, J., Raoul, J.L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P.R., Santoro, A., Beaugrand, M., Sangiovanni, A., Porta, C., Gerken, G., Marrero, J.A., Nadel, A., Shan, M., Moscovici, M., Voliotis, D. and Llovet, J.M. (2012) Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. Journal of Hepatology, 57, 821-829.
http://dx.doi.org/10.1016/j.jhep.2012.06.014

has been cited by the following article:

• TITLE: Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

  AUTHORS: Fernando Gomes Romeiro, Luciana Yumi Odani Sigahi, Matheus Alvarez, Fabio da Silva Yamashiro, Fábio Cardoso de Carvalho, Leonardo Pelafsky, Talles Bazeia Lima, Letícia de Campos Franzoni, José Ricardo de Arruda Miranda, Giovanni Faria Silva

  KEYWORDS: Hepatocellular Carcinoma, Cirrhosis, Arterial Chemoembolization, Sorafenib

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.3, March 19, 2015

  ABSTRACT: Introduction: Hepatocellular carcinoma (HCC) is a leading cause of mortality among cirrhotic patients, and current guidelines recommend single-treatment modalities according to patient and liver disease classifications. New studies have shown promising results from combining locoregional and systemic treatments, but most of them were limited to Child-Pugh A patients due to toxicity concerns. Aim: The objective of this study was to analyze survival rates of Child-Pugh A and B patients with intermediate HCC tumors treated with transarterial chemoembolization (TACE) followed by full-dose sorafenib usage. Material and methods: a retrospective analysis of 37 cirrhotic patients (Child-Pugh A and B rates = 23/14) treated with TACE and TACE followed by sorafenib usage (17 and 20 patients, respectively). Results: The mean survival was 379 days in the combined treatment group and 151 days in the single-treatment group (p = 0.007). There were no differences in survival according to the Child-Pugh classification. Conclusions: sorafenib after TACE can be an option for selected cirrhotic patients with intermediate HCC tumors if this combined approach is cautiously performed on an individualized schedule. Our results suggest that the Child-Pugh classification should not be a limitation to this combined treatment.